Why Is TRAVERE THERAPEUTICS (TVTX) Stock Up Today?

Travere Therapeutics (TVTX) surged 12.03% to $62.76 in a single session, driven by strong second quarter results and analyst upgrades. The stock’s performance was fueled by a 96% year-over-year increase in FILSPARI sales and a positive reception of its FSGS launch. Analysts from multiple firms raised price targets, reflecting confidence in the company’s growth trajectory.

What Happened

Travere Therapeutics reported second quarter 2026 results on August 4, 2026, with FILSPARI sales rising 96% year-over-year and 2,012 new patient starts. The company also announced $141 million in revenue and a peak annual FILSPARI sales potential of more than $3 billion. These results were highlighted in an SEC 8-K filing and discussed during the company’s earnings call on August 4. The FSGS launch has exceeded expectations, contributing to the stock’s upward momentum. In addition, Stifel, TD Cowen, Citigroup, Evercore ISI Group, and Guggenheim all raised price targets for the stock, reinforcing investor confidence.

What The Data Shows

Travere Therapeutics closed at $62.76, a 12.03% increase for the session. The stock has traded between $15.42 and $60.10 over the past 52 weeks, indicating a strong upward trend. The company has a market capitalization of $5.1 billion and reported revenue growth of 96% TTM, despite an unprofitable status with an EPS TTM of -0.51 and a net margin of -4.0%. Recent insider transactions show three sales totaling $867,000 over the past 90 days, with no insider buying reported.

What To Watch

Travere Therapeutics is scheduled to participate in investor conferences, with the first presentation on August 11. The company’s continued performance in FILSPARI sales and FSGS launch progress will be key indicators for future stock movement. Investors should also monitor analyst coverage and any further price target adjustments.